BIOCYTOGEN-B (02315) elected Li Yan as a worker representative director of the second board of directors.
Baiosei map B (02315) issued an announcement. The board of directors of Baiosei Map (Beijing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") recently received a written resignation report from Ms. Zhang Haichao, a non-independent director of the Company. Due to internal work adjustments within the company, Ms. Zhang Haichao has applied to resign from the position of non-independent director of the second board of directors of the company. After resigning from the above position, Ms. Zhang Haichao will continue to hold other positions within the company.
BIOCYTOGEN-B (02315) announced that the Board of Directors of Beike Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as the "Company") recently received a written resignation report from Ms. Zhang Haichao, a non-independent director of the company. Due to internal work adjustments within the company, Ms. Zhang Haichao has applied to resign from the position of non-independent director of the second session of the Board of Directors. After resigning from the aforementioned position, Ms. Zhang Haichao will continue to serve in other positions within the company.
On December 5, 2025, the company held a staff representative congress and elected Ms. Li Yan as the staff representative director of the second session of the Board of Directors, with a term of office from the date of the company's stock listing on the Sci-Tech Innovation Board until the expiration of the term of office of the second session of the Board of Directors.
Related Articles

GME GROUP (08188) spent 104,000 Hong Kong dollars to repurchase 100,000 shares on December 11th.

Shareholder Zheng Zhikai of Shanghai Weihong Electronic Technology (300508.SZ) plans to reduce his holdings by no more than 1.15% of the shares.

CMS(00867) Y-3, a heavyweight innovative drug for the treatment of stroke, has been accepted for NDA in China for injection use.
GME GROUP (08188) spent 104,000 Hong Kong dollars to repurchase 100,000 shares on December 11th.

Shareholder Zheng Zhikai of Shanghai Weihong Electronic Technology (300508.SZ) plans to reduce his holdings by no more than 1.15% of the shares.

CMS(00867) Y-3, a heavyweight innovative drug for the treatment of stroke, has been accepted for NDA in China for injection use.

RECOMMEND

McDonald’s to Evaluate Franchisee Pricing for Customer Value Under Revised Standards
10/12/2025

Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025

Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025


